Skip to main content
SpringerLink
Log in

Psychopharmaka

  • Chapter
Arzneiverordnungs-Report 2016

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren nochmals auffällig verändert. Im Durchschnitt haben sich die Verordnungen der Antidepressiva in der letzten Dekade fast verdoppelt mit abflachender Tendenz seit 2012.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abbas S, Ihle P, Adler JB, Engel S, Günster C, Linder R, Lehmkuhl G, Schubert I (2016): Psychopharmaka-Verordnungen bei Kindern und Jugendlichen in Deutschland. Bundesweite Auswertung von über 4 Millionen gesetzlich Versicherten von 2004 bis 2012. Dtsch Ärztebl. 113: 396–403

    Google Scholar 

  • Aderhold V, Weinmann S, Hägele C, Heinz A (2014): Frontale Hirnvolumenminderung durch Antipsychotika? Nervenarzt 86: 302–323

    Article  Google Scholar 

  • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004): Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27: 596–601

    Article  Google Scholar 

  • Anderson IM (2000): Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58: 19–36

    Article  CAS  PubMed  Google Scholar 

  • Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005): Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3: 449–456

    Article  PubMed  PubMed Central  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): Suizide und Suizidversuche unter Bupropion. Deutsches Ärzteblatt 101: A 2139–2140

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2006): Hypersexualität unter Aripiprazol. Dtsch Ärztebl 103: A3518

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2011): Aus der UAW-Datenbank: Abhängigkeitspotenzial unter Pregabalin (Lyrica®). Dtsch Ärztebl 108: A 183

    Google Scholar 

  • Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014): Antipsychotika-Verordnungen bei Kindern und Jugendlichen:Auswertung von Daten einer gesetzlichen Krankenkasse für den Zeitraum 2005–2012. Dtsch Arztebl 111: 25–34

    Google Scholar 

  • Baghai TC, Lieb M, Möller HJ, Bschor T, Härter M, Schauenburg H (2011): Antidepressiva bei leichten depressiven Störungen. Psychiatr Prax 38: 270–273

    Article  PubMed  Google Scholar 

  • Bauer M, Adli M, Bschor T, Pilhatsch M, Pfennig A, Sasse J, Schmid R, Lewitzka U (2010): Lithium’s emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 62: 36–42

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Grof P, Müller-Oerlinghausen B (Hsgb.) (2006): Lithium in Neuropsychiatry: The Comprehensive Guide. Informa healthcare. Oxon (UK)

    Google Scholar 

  • Baumann P, Spies M, Möller HJ, Kasper S, Bitter I, Laux G (2016): A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World J Biol Psychiatry. 2016 Apr 6: 1–10. [Epub ahead of print]

    Article  Google Scholar 

  • Bendz H, Schön S, Attman PO, Aurell M (2010): Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 77: 219–224

    Article  CAS  PubMed  Google Scholar 

  • Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M (2013): Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med. 2013 Feb 11;11:33. doi:10.1186/1741-7015-11-33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Braun C, Bschor T, Franklin J, Baethge C (2016): Suicides and suicide attempts during long-term treatment with antidepressants: A meta-analysis of 29 placebo-controlled studies including 6,934 patients with major depressive disorder. Psychother Psychosom 85: 171–179

    Article  PubMed  Google Scholar 

  • Bschor T, Adli M (2009): Therapie depressiver Erkrankungen. Dtsch Ärztebl 105: A 782–A 792

    Google Scholar 

  • Bschor T, Hartung HD (2008): Antidepressiva Kombinationsbehandlungen. In Bschor T (Hrsg): Behandlungsmanual therapieresistenter Depressionen. Kohlhammer, Stuttgart, S. 86–101

    Google Scholar 

  • Bschor T, Müller-Oerlinghausen B (2014): Antidepressiva verringern nicht das Risiko von Suiziden oder Suizidversuchen bei depressiven Patienten Eine Entgegnung zur Presseerklärung der Deutschen Gesellschaft für Psychiatrie, Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). Arzneiverordnung in der Praxis 41: Heft 2, 2–4

    Google Scholar 

  • Bschor T, Müller-Oerlinghausen B, Stoppe G, Hiemke C (2014): Neue Fakten zur Phasenprophylaxe der bipolar affektiven Erkrankung. Nervenarzt 85: 1166–1170

    Article  CAS  PubMed  Google Scholar 

  • Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C (2012): Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533

    PubMed  PubMed Central  Google Scholar 

  • Cipriani A, Hawton K, Stockton S, Geddes JR (2013): Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346: f3646, doi:10.1136/bmj.f3646

    PubMed  Google Scholar 

  • Cipriani A, Rendell J, Geddes JR (2010): Olanzapine in the longterm treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 24: 1729–1738

    Article  CAS  PubMed  Google Scholar 

  • Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002): Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28: 75–84

    Article  PubMed  Google Scholar 

  • Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L (2013): European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 23: 1208–1218

    Article  CAS  PubMed  Google Scholar 

  • Collins JC, McFarland BH (2008): Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. J Affect Disord 107: 23–28

    Article  CAS  PubMed  Google Scholar 

  • Connolly KR, Thase ME (2011): If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71: 43–64

    Article  CAS  PubMed  Google Scholar 

  • Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011): Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343: d4551. doi:10.1136/bmj.d4551

    Article  PubMed  PubMed Central  Google Scholar 

  • Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J (2015): Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database. BMJ 2015 Feb 18; 350: h517. doi:10.1136/bmj.h517.

    Google Scholar 

  • Coyle CM, Laws KR (2015): The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacol 30: 152–163

    Google Scholar 

  • Croissant B, Mann K (2004): Pharmakologische Rückfallprophylaxe bei Alkoholabhängigkeit. Psychoneuro 30: 30–36

    Google Scholar 

  • Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG (2015): Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet 385: 2190–2196

    Article  PubMed  Google Scholar 

  • Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J (2016): Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 81: 773–783

    Article  CAS  PubMed  Google Scholar 

  • Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS (2009): Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675–682

    Article  PubMed  Google Scholar 

  • Dersch R, Zwernemann S, Voderholzer U (2011): Partial status epilepticus after electroconvulsive therapy and medical treatment with bupropion. Pharmacopsychiatry 44: 344–346

    Article  CAS  PubMed  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN, Federführung) (2015): S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 2. Auflage, AWMF-Register-Nr.: nvl-005. Internet: http://www.depression.versorgungsleitlinien.de

  • Deutsche Gesellschaft für Soziale Psychiatrie (DGSP) (2009): DGSP-Memorandum zur Anwendung von Antipsychotika. Soziale Psychiatrie 34: 50–51

    Google Scholar 

  • De Zwaan M, Gruss B, Müller A, Graap H, Martin A, Glaesmer H, Hilbert A, Philipsen A (2012): The estimated prevalence and correlates of adult ADHD in a German community sample. Eur Arch Psychiatry Clin Neurosci 262: 79–86

    Article  PubMed  Google Scholar 

  • Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D (2013): Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs 27: 1081–1092

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fountoulakis KN, Möller HJ (2010): Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14: 405–412

    Article  PubMed  CAS  Google Scholar 

  • Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010): Antidepressant drug effects and depression severity: a patient-level metaanalysis. JAMA 303: 47–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Friedmann PD (2013): Alcohol use in adults. N Engl J Med 368: 1655–1656

    Article  CAS  PubMed  Google Scholar 

  • Frye MA, Ketter TA, Leverich GS, Huggins T, Lantz C, Denicoff KD, Post RM (2000): The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 61: 9–15

    Article  CAS  PubMed  Google Scholar 

  • Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, Morgan L, Lohr KN (2008): Comparative benefits and harms of second- generation antidepressants: Background paper for the American College of Physicians. Ann Int Med 149: 734–750

    Article  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321: 1371–1376

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library—Issue 1

    Google Scholar 

  • Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S (2014): Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry 205: 44–51

    Article  CAS  PubMed  Google Scholar 

  • Gerhard T, Devanand DP, Huang C, Crystal S, Olfson M (2015): Lithium treatment and risk for dementia in adults with bipolar disorder: population-based cohort study. Brit J Psychiatry 207: 46–51

    Google Scholar 

  • Gibbons RD, Brown CH, Hur K, Marcus SM, Baumikh DK, Erkenmann JJ (2007): Early evidence on the effects of regulators’ suicidality warnings on prescriptions and suicide in children and adolescents. Am J Psychiatry 164: 1356–1363

    Article  PubMed  Google Scholar 

  • Goldberg TE, Gomar JJ (2009): Targeting cognition in schizophrenia research: from etiology to treatment. Am J Psychiatry 166: 631–634

    Article  PubMed  Google Scholar 

  • Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467–1473

    Article  CAS  PubMed  Google Scholar 

  • Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441

    Article  CAS  PubMed  Google Scholar 

  • from the International AMSP Project between 1994 and 2009. Affect Disord 136: 534–1542

    Google Scholar 

  • Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf GA, Sauer H, Tegeler J, Wetterling T (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40: 179–190

    Article  CAS  PubMed  Google Scholar 

  • Grof P (2013): Melancholia: a distinct entity? Can J Psychiatry 58: 181–182

    PubMed  Google Scholar 

  • Grof P, Müller-Oerlinghausen B (2009): A critical appraisal of lithium’s efficacy and effectiveness: the last 60 years. Bipolar Disord 11 (Suppl 2): 10–19

    Article  CAS  PubMed  Google Scholar 

  • Grohmann R, Engel RR, Geissler KH, Rüther E (2004): Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry 37 Suppl 1: S27–38

    PubMed  Google Scholar 

  • Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M (2013): Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013 Dec 17; (12): CD008851

    Google Scholar 

  • Hägg S, Bate A, Stahl M, Spigset O (2008): Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 31: 685–694

    Article  PubMed  Google Scholar 

  • Hansen R, Gaynes B, Thieda P, Gartlehner G, Deveaugh-Geiss A, Krebs E, Lohr K (2008): Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 59: 1121–1130

    Article  PubMed  PubMed Central  Google Scholar 

  • Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP (2016): Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 15: 53–58

    Google Scholar 

  • Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79

    Article  PubMed  Google Scholar 

  • Hegerl U, Mergl R, Quail D, Schneider E, Hundemer HP, Linden M (2012): Does pain improve earlier than mood in depressed patients with painful physical symptoms treated with duloxetine? Pharmacopsychiatry 45: 114–118

    Article  CAS  PubMed  Google Scholar 

  • Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011): AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195–235

    Article  Google Scholar 

  • Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX (2014): Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161: 242–248

    Article  PubMed  Google Scholar 

  • Janhsen K, Roser P, Hoffmann K (2015): Probleme der Dauertherapie mit Benzodiazepinen und verwandten Substanzen. Dtsch Ärztebl 112: 1–7

    Google Scholar 

  • Jans T, Warnke A (2010): Die britische NICE-Guidance zu Diagnose und Therapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter. Arzneiverordnung in der Praxis. 37: 4–6

    Google Scholar 

  • Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006): Randomized controlled trial of the effect on Quality of Life of secondvs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63: 1079–1087

    Article  CAS  PubMed  Google Scholar 

  • Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A (2009): Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess 13: iii-iv, ix-xi, 1–159

    Google Scholar 

  • Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008): Initial severity and antidepressant benefit: a meta-analysis of data submitted to the Food and Drug Administration. PloS Med 5: e45

    Google Scholar 

  • KlauberJ, Günther C, Gerste B, Robra BP, Schmacke N (Hsgb) (2016): Versorgungsreport 2015/2016. Schwerpunkt: Kinder und Jugendliche. Schattauer Verlag Stuttgart 2016

    Google Scholar 

  • Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010): Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 Dec 8; (12): CD008141

    Google Scholar 

  • Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S (2009): Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD006569

    Google Scholar 

  • Kupfer DJ, Frank E, Phillips ML (2012): Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379: 1045–1055

    Article  PubMed  Google Scholar 

  • La Torre A, Conca A, Duffy D, Giupponi G, Pompili M, Grözinger M (2014): Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 46: 201–208

    Google Scholar 

  • Lepping P, Sambhi RS, Whittington R, Lane S, Poole R (2011): Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 198: 341–345

    Article  PubMed  Google Scholar 

  • Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a): How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14: 429–447

    Google Scholar 

  • Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b): Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41

    Google Scholar 

  • Leucht S, Wahlbeck K, Hamann J, Kissling W (2003): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet 361: 1581–1589

    Article  CAS  PubMed  Google Scholar 

  • Lewitzka U, Bauer M, Felber W, Müller-Oerlinghausen B (2013): Suizidprophylaktische Wirkung von Lithium. Aktueller Forschungsstand und Implikationen für die Therapie affektiver Störungen Nervenarzt 84: 294–306

    Article  CAS  PubMed  Google Scholar 

  • Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M (2015):The suicide protective effects of lithium:more than 20 years of evidence. Int. J Bipol Dis, i.Dr.

    Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209–1233

    Article  CAS  PubMed  Google Scholar 

  • Linde K, Kriston L, Rücker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A (2015): Efficacy and acceptability of pharmacological treatments for ndepressive disorders in primary care: a systematic review and network meta-analysis. Am Fam Med 13: 69–79

    Article  Google Scholar 

  • MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326: 1014–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software

    Google Scholar 

  • Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, Wang Z, Timmer M, Sultzer D, Shekelle PG (2011): Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306: 1359–1369

    Article  CAS  PubMed  Google Scholar 

  • Maher AR, Theodore G (2012): Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 18 (5 Suppl B): S1–20

    Google Scholar 

  • McDonagh M, Peterson K, Carson S, Fu R, Thakurta S (2010): Drug Class Review: Atypical Antipsychotic Drugs. Final Update 3 Report. Portland (OR): Oregon Health & Science University; July 2010. Internet: http://www.ncbi.nlm.nih.gov/books/NBK50583/

  • McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS (2014): Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311: 1978–1987

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • McEvoy JP;Lieberman JA;Stroup TS;Davis SM;Meltzer HY;Rosenheck RA;Swartz MS;Perkins DO;Keefe RS;Davis CE;Severe J;Hsiao JK; CATIE Investigators (2006): Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163: 600–610

    Article  PubMed  Google Scholar 

  • McGorry P, Alvarez-Jimenez M, Killackey E (2013): Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more. JAMA Psychiatry 70: 898–900

    Google Scholar 

  • McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR (2012): Lithium toxicity profile: a systematic review and meta-analysis. Lancet 379: 721–728

    Article  CAS  PubMed  Google Scholar 

  • Mészáros A, Czobor P, Bálint S, Komlósi S, Simon V, Bitter I (2009): Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol 12: 1137–1147

    Article  PubMed  CAS  Google Scholar 

  • Miyamoto S, Miyake S, Jarskog LF, Fleischhacker WW, Lieberman JA (2012): Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17: 1206–1227

    Article  CAS  PubMed  Google Scholar 

  • Molina BSG, Florey K, Hinshaw SP, Greiner, AR, Arnold E, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliot GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007): Delinquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46: 1028–1040

    Article  PubMed  Google Scholar 

  • Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebocontrolled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65

    Article  PubMed  Google Scholar 

  • Moncrieff J (2008): Steht die Psychiatrie zum Verkauf an? Sozialpsychiatr Informationen 38: 8–18

    Google Scholar 

  • Moncrieff J, Kirsch I (2005): Efficacy of antidepressants in adults. BMJ 331: 155–157

    Article  PubMed  PubMed Central  Google Scholar 

  • MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086

    Google Scholar 

  • Müller-Oerlinghausen B (2011): Antidepressiva sind nur bei sehr schwerer Depression Placebo überlegen. Arzneiverordnung in der Praxis 39: 60–62

    Google Scholar 

  • Müller-Oerlinghausen B (2012): Sind atypische Antipsychotika Mittel erster Wahl bei bipolaren Störungen? Kontra. Nervenarzt 83: 1191–1192.

    Article  PubMed  Google Scholar 

  • National Institute for Health and Care Excellence (2014): Psychosis and schizophrenia in adults: prevention and management. Clinical guideline. Internet: nice.org.uk/guidance/cg178

    Google Scholar 

  • Offidani E, Fava GA, Tomba E, Baldessarini RJ (2013): Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. Psychother Psychosom 82: 132–141

    Article  PubMed  Google Scholar 

  • Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, For The Cafe Investigators (2009): Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 111: 9–16

    Article  PubMed  Google Scholar 

  • Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK; Clinical Efficacy Assessment Subcommittee of American College of Physicians (2008): Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149: 725–733

    Article  PubMed  Google Scholar 

  • Ray WA, Chung CP, Murray KT, Hall K, Stein CM (2009): Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360: 225–235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reeves RR, Ladner ME (2010): Antidepressant-induced suicidality: an update. CNS Neurosci Ther 16: 227–234

    PubMed  Google Scholar 

  • Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group (2010): Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 18: 136–145

    Article  PubMed  PubMed Central  Google Scholar 

  • Rösner S, Leucht S, Lehert P, Soyka M (2008): Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 22: 11–23

    Article  PubMed  Google Scholar 

  • Sayadipour A, Mago R, Kepler CK, Chambliss RB, Certa KM, Vaccaro AR, Albert TJ, Anderson DG (2012): Antidepressants and the risk of abnormal bleeding during spinal surgery: a case-control study. Eur Spine J 21: 2070–2078

    Article  PubMed  PubMed Central  Google Scholar 

  • Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S (2011): A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123: 247–265

    Article  CAS  PubMed  Google Scholar 

  • Schwarz MJ (2016): Therapeutic drug monitoring for individualised risk reduction in psychopharmacotherapy. Trends in Analytical Chemistry June 2016 DOI:10.1016/j.trac.2016.05.027

    Google Scholar 

  • Shine B, McKnight RF, Geddes JR (2015): Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015 May 20 [Epub ahead of print]

    Google Scholar 

  • Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008): Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165: 1420–1431

    Article  PubMed  Google Scholar 

  • Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404

    Article  PubMed  Google Scholar 

  • Smith EG, Austin L, Kim HM, Eisen SV, Kilbourne AM, Miller DR, K, Hannemann C, Sauer BC, Valenstein M (2015): Mortality associated with lithium and valproate treatment of US Veterans Health Administration patients with mental disorders. Brit J Psychiatry 207: 55–63.

    Google Scholar 

  • Sobanski E, Sabljic D, Alm B, Baehr C, Dittmann RW, Skopp G, Strohbeck-Kuehner P (2012): A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45: 100–107

    Article  CAS  PubMed  Google Scholar 

  • Song HR, Kwon YJ, Woo YS, Bahk WM (2015): Effects of mirtazapine on patients undergoing naturalistic diabetes treatment: A follow-up study extended from 6 to 12 months. J Clin Psychopharmacol 35: 730–731

    Article  PubMed  Google Scholar 

  • Soyka M, Lieb M (2015): Recent developments in pharmacotherapy of alcoholism. Pharmacopsychiatry 48: 123–135

    Article  CAS  PubMed  Google Scholar 

  • Spielmans GI (2008): Duloxetine does not relieve painful psychological symptoms in depression. A metaanalysis. Psychother Psychosom 77: 12–16

    Article  PubMed  Google Scholar 

  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013): Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10(3): e1001403

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sterke CS, Ziere G, van Beeck EF, Looman CW, van der Cammen TJ (2012): Dose-response relationship between selective serotonin re-uptake inhibitors and injurious falls: a study in nursing home residents with dementia. Br J Clin Pharmacol 73: 812–820

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (2015): Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015 Nov 25; (11): CD009885

    Google Scholar 

  • Stübner S, Grohmann R, von Strahlendorff I, Rüther E, Möller HJ, Müller-Oerlinghausen B, Engel R, Horvarth A, Greil W (2010): Suicidality as a rare advserse event of antidepressant medication. Report from the AMSP Multicenter Drug Surveillance Project. J Clin Psychiatry 71: 1293–1307

    Article  PubMed  Google Scholar 

  • Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26

    Article  CAS  PubMed  Google Scholar 

  • Toffol E, Hätönen T, Tanskanen A, Lönnqvist J, Wahlbeck K, Joffe G, Tiihonen J, Haukka J, Partonen T (2016): Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study. J Affect Disord 183: 159–165

    Article  CAS  Google Scholar 

  • Tranulis C, Skalli L, Lalonde P, Nicole L, Stip E (2008): Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 31: 7–20

    Article  CAS  PubMed  Google Scholar 

  • Tsapakis EM, Gamie Z, Tran GT, Adshead S, Lampard A, Mantalaris A, Tsiridis E (2012): The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2 7: 156–169

    Article  Google Scholar 

  • Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D (2011): Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8: e1000434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ujeyl M, Müller-Oerlinghausen B (2012): Antidepressiva zur Behandlung der Depression bei Palliativpatienten: Eine systematische Übersicht. Schmerz 26: 523–536

    Article  CAS  PubMed  Google Scholar 

  • Vitiello B, Correll C, van Zwieten-Boot B, Zuddas A, Parellada M, Arango C (2009): Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19: 629–635

    Article  CAS  PubMed  Google Scholar 

  • Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuropsychopharmacol 10: 211–217

    Article  CAS  PubMed  Google Scholar 

  • Wagstaff AJ, Ormrod D, Spencer CM (2001): Tianeptine: a review of its use in depressive disorders. CNS Drugs 15: 231–259

    Article  CAS  PubMed  Google Scholar 

  • Walder A, Greil W, Baumann P (2009): Drug-induced Pisa syndrome under quetiapine. Prog Neuropsychopharmacol Biol Psychiatry 33: 1286–1287

    Article  CAS  PubMed  Google Scholar 

  • Weinmann S, Read J, Aderhold V (2009): Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 113: 1–11

    Article  PubMed  Google Scholar 

  • Wensel TM, Powe KW, Cates ME (2012): Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46: 424–429

    Article  PubMed  CAS  Google Scholar 

  • Whitaker R (2010): Anatomy of an epidemic. Magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. Crown Publishing, New York

    Google Scholar 

  • Wolter DK (2009): Risiken von Antipsychotika im Alter, speziell bei Demenzen. Eine Übersicht. Z Gerontopsychol psychiatr 22: 17–56

    Google Scholar 

  • Zhang J, Mathis MV, Sellers JW, Kordzakhia G, Jackson AJ, Dow A, Yang P, Fossom L, Zhu H, Patel H, Unger EF, Temple RJ (2015): The US Food and Drug Administration’s perspective on the new antidepressant vortioxetine. J Clin Psychiatry 76: 8–14

    Article  PubMed  Google Scholar 

  • Zhou S, Chan E, Pan SQ, Huang M, Lee EJ (2004): Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 18: 262–276

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Straße 10, 13125, Berlin-Buch

    Prof. Dr. med. Martin J. Lohse

  2. Bartningallee 11–13, 10555, Berlin

    Prof. Dr. med. Bruno Müller-Oerlinghausen

Authors
  1. Prof. Dr. med. Martin J. Lohse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Bruno Müller-Oerlinghausen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lohse, M., Müller-Oerlinghausen, B. (2016). Psychopharmaka. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2016. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50351-5_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50351-5_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50350-8

  • Online ISBN: 978-3-662-50351-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation